Structure Therapeutics

GPCR · NASDAQ

$22.88+$0.87 (+3.95%)TodayMarket closed ·
Prev close $22.01

Latest news

  • NewsVandana Singh

    Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data

  • Press releaseGlobe Newswire

    Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

  • Press releaseGlobe Newswire

    Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

  • NewsStjepan Kalinic

    Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model

  • Press releaseGlobe Newswire

    Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

  • Press releaseGlobe Newswire

    Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

  • Press releaseGlobe Newswire

    Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

  • NewsVandana Singh

    What's Going On With Structure Therapeutics Stock On Wednesday?

  • NewsVandana Singh

    Structure Therapeutics Stock Explodes As Much-Awaited Experimental Oral Drug Trial Shows Weight Loss Of 16%

  • Press releaseGlobe Newswire

    Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

  • Press releaseGlobe Newswire

    Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

  • NewsVandana Singh

    Weight Loss Drugs Market Is Crowded But Structure Therapeutics CEO Has A Strategy For It

  • NewsVandana Singh

    Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments

  • News

    Structure Therapeutics CEO Expects Pills To Capture 25% To 50% Of GLP-1 Weight-Loss Market By 2030; Says Strategic Partner For Commercialization Of Its Medicine Needs To Have Strong Relationships With Primary Care Doctors

  • News

    10 Health Care Stocks Whale Activity In Today's Session

  • NewsAvi Kapoor

    Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday

  • NewsHillary Remy

    The Year-End 2025 Biotech Rally And What It Means For 2026

  • NewsChris Katje

    Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • NewsAvi Kapoor

    Crude Oil Falls Over 1%; Structure Therapeutics Shares Jump

  • NewsAvi Kapoor

    Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana And Other Big Stocks Moving Higher On Monday

  • News

    12 Health Care Stocks Moving In Friday's After-Market Session

  • News

    FDA Launches Green List To Protect Americans From Illegal Imported GLP-1 Drug Ingredients

  • NewsVandana Singh

    Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

  • NewsAvi Kapoor

    uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday

  • NewsAvi Kapoor

    Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

  • NewsVandana Singh

    Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition

  • NewsAvi Kapoor

    Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday

  • NewsAvi Kapoor

    Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

  • NewsAvi Kapoor

    ASML Reports Q2 Results, Joins Spirit Airlines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.